HLB and Elevar Therapeutics (Elevar) announced on the 26th that they have signed Mark Gelder, M.D. as Vice President of Medical Affairs at Elevar for fast global clinical trials and market launches.
Dr. Gelder majored in Internal Medicine and Obstetrics and Gynecology at the University of Virginia School of Medicine and published many research papers, particularly as a clinical trial researcher in the field of gynecological cancer. Since then, he has been working with Pfizer, Wyeth, and Bayer as Medical Affairs for 17 years, participating in the development of anticancer drugs and leading the approval and release of various products. Dr. Gelder will lead Elevar's global clinical organization and lead the overall management and development strategy on the market and clinical trials of Rivoceranib and Apealea.
“Dr. Gelder is a person who has demonstrated excellent leadership based on various experiences at global pharmaceutical companies,” said Alex Kim, CEO of Elevar, “With his consolidation, Elevar's new drug commercialization capacity will be strengthened and commercialization is expected to proceed rapidly.”